Using a numerical integration method, concentration-time data were simulated using the one-compartment open model both with bolus intravenous administration and oral administration (first-order absorption) after multiple doses administered at constant time intervals and for
INTRODUCTION
The Michaelis-Menten equation (1) was first applied in pharmacokinetics to explain elimination of ethanol from human serum by Lundquist and Wolthers (2) 
Wagner
Wagner (3) . More recently the equation has been applied to serum and plasma concentrations of phenytoin (4) (5) (6) (7) . Some properties of the equation and its integrated form were given by Wagner (8) . Tsuchiya and Levy (9) published some plots of the ratio plateau level/dose vs. dose after simulating multiple dose levels for the one-compartment open model with (a) first-order elimination, (b) Michaelis-Menten elimination, and (c) parallel first-order and Michaelis-Menten elimination. However, there appears to be no published information on the time required to reach steady-state levels when elimination obeys Michaelis-Menten kinetics. In the case of phenytoin monitoring, authors (5) (6) (7) are measuring a phenytoin concentration at some time within one or more dosage intervals, but differ as to when during the dosage interval the sample is taken or after how many doses. Eadie (10) states that the "5 times half-life rule works adequately" for phenytoin as for drugs eliminated by first-order kinetics. Intuitively, this appeared to be incorrect to this author. This study was undertaken to obtain quantitative information by a simulation technique concerning the time required to reach steady state and methods to predict steady-state concentrations from concentrations "observed" before steady-state was attained. 
THEORETICAL
where ko is the constant infusion rate (mass/time), Va is the volume of distribution, Vm is the maximal velocity [mass/(volume• so that VaVm is the maximal velocity (mass/time), Km is the Michaelis constant (mass/volume), and C~ is the steady-state concentration (mass/volume). For the n-compartment open mammillary model with central compartment elimination only, equation 1 also applies, but Va is replaced by Va~s as defined by gdss = (1 3r-k12/ k21 "Jr-'" + k ln/ k,1) Vp (2) where k12 and k21 are the transfer rate constants between compartments 1 and 2, k~n and k,1 are the transfer rate constants between compartment 1 and the nth compartment, and Vp is the volume of the central compartment.
For intermittent intravenous administration with a dose D administered every ~-hr, equation 3 would apply, where the average steady-state concentration, C'ss, is given by equation 4:
Thus the k0 of equation 1 is replaced by the "dose rate," D/% in equation 3 and C~ is replaced by tiffs. Analogously, for oral administration one would expect equations 3 and 4 also to apply, since, as in linear pharmacokinetics, the absorption rate constant would not appear in such an equation; the only change would be that for oral administration the D of equation 3 would mean the amount of drug which reaches the circulation intact.
In therapeutic drug monitoring the minimum concentrations (just before the next dose) are readily measured, but not the average concentration during any given dosage interval, since the latter require several blood samples, but th~ former require only one sample per dosage interval. One question to be answered by the study performed was whether equation 3 applies if (~ is replaced by min rain Css , where C~ is the minimum concentration at steady state.
EXPERIMENTAL
Two sets of simulations were performed. In both cases the differential equations were numerically integrated using the Runge-Kutta method and an electronic calculator. Numerical values of the constants used were similar to some of those reported by Richens (5) for phenytoin.
Simulated Intravenous Data
Equation 5 was numerically integrated for each dosage interval:
In equation 5, C is the simulated plasma concentration at time t after the nth dose of Size D and the other symbols are as defined in the Theoretical section. Constants used were Vm = 15 mg/(liters • Km = 12 mg/liter, D = 200, 250, 300, 400, and 500 mg, corresponding to Co = 5, 6.25, 7.5, 10, and 12.5 mg/liter, respectively, since the assumed volume of distribution, Vd, was 40 liters. The "dose" was given once a day, hence the dosage interval, ~" = 1 day, and the dose rates, D/T, were the same as the doses. The step height employed was 0.01 day. When D = 200, Co = 5 for the first day; for subsequent days, Co was equal to 5 plus the value of C at 24 hr after the previous dose. During these simulations, only the maximax rain mum, C~ , and minimum, C. , concentrations for each dose were recorded, where n is the dose number.
Simulated Oral Data
Equation 6 was numerically integrated for each dosage interval:
where ka is the first-order rate constant for absorption and the other symbols are as defined above. Constants used were k, = 0.25 hr -a, Vm = 12 mg/(liters x day), Km= 12 mg/liter, D = 100, 150, 300, 400, and 600, corresponding to Co--1.67, 2.5, 5, 6.67, and 10 mg/liter, respectively, since the assumed Va was 60 liters. Again ~-= 1 day, hence the dose rates were the same as the doses. During these simulations, the concentrations at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 hr, as well as the maximum concentration, C m~, and the time of the maximum cocncentration, t m"~, were recorded for each dose. The average concentration during each dosage interval, C,, was estimated by estimating the area under the C, t curve [mg/(liters • hr)] by trapezoidal rule, then dividing this area by r (in this case 24 hr).
Treatment ot Data
Initial estimates of the asymptotic steady-state concentrations, Cs rain rain __ and C~, were obtained by extrapolating linear plots of C~ i" vs. C,+1 C~ i" or C, vs. C,+1-C, (see later Fig. 2 ), since the concentrations were obtained at equal time intervals (11, 12) . Initial estimates of the rate parameters, A a and A2, were obtained by application of the back-projection C,,+1 -C. or technique to the differences, rain min Cn+l -Cn.
Final estimates of the steady-state concentrations and the Ai's were rain obtained by nonlinear least-squares fitting of C.,n or C. ,n data to one of equations 7-10, using the program NONLIN (13) and a high-speed digital computer.
C. = Cs~(1 -e -~1") rain Aln
Cm~B=C~ (1-e )
G = G(1 -e -~'") + C~(1 -e -~=~)
Cn rain = CI(1 -e -;tin) + C2(1 --e -xan)
(8)
(lo)
From equation 9 one obtains C~s = C1 + C2 for n ~ co and from equation 10 one obtains C~ in = Ca + C2 for n -> oo. It should be noted, since n = 1, 2, 3 .... , etc., days, that the A~'s have dimension day -1. In the fittings the concentrations were weighted 1/Ci and A1 < A2. The half-life, (t1/2)al, corresponding to each estimated A1 value, was obtained by dividing the A 1 value into the natural logarithm of 2. For each data set these half-life values were plotted against the corresponding steady-state concentrations.
The steady-state concentrations were also fitted, via NONLIN, to either equation 11 or 12, also with reciprocal weighting.
Equation 12 is just a rearranged form of equation 3. In equation 11, K~ p and V~ p are operationally useful parameters, but are not the same as the Km and Vm used to generate the data.
The parameters of equations 11 and 12 were also estimated by use of various linear transformations of the equations (14-18). Figure 1 is a plot of the minimum concentration after the nth dose, rain Cn , vs. the dose number, n, for the intravenous simulation. Similar plots (not shown) were obtained when C ma• from the intravenous simuhtions or C~ ax, Cn, and C~ in from the oral simulations were plotted vs. n. One can immediately perceive that the higher the dose, the higher the steady-state concentration and the longer the time required to reach that concentration.
RESULTS
If concentrations are measured at equal time intervals, as in the simulations, the difference method, as introduced into pharmacokinetics by Amidon et al. (1 1) , and modified by Wagner and Ayres (12) , could be applied to estimate the asymptotic steady-state concentrations from data obtained before steady state was attained. Examples are shown in Fig. 2 . During the monitoring of minimum phenytoin concentrations, similar plots to those illustrated in Fig. 2 could be constructed. In Fig. 2 the plots are linear since data of each set were chosen in the dose number range where the approach to steady state is described by single exponential function (equation 8) . If all the data of a given set are described by a biexponential equation (equation 9 or 10) as n increases, e -A2n ~0, hence the second term on the right-hand sides of equations 9 and 10 approaches (72 and the final approach is monoexponential in all cases. If all or essentially all data of a set where the entire approach is described by a biexponential equation are included in the difference plot, then the difference data may be fitted with the equation of a parabola, as illustrated in Fig. 3 . Data shown at the Once estimates of the asymptotic Css and C~ ~ were obtained by the difference method, then the In (Cs~-C,), t and In (C~ i" -cmi"), t data were analyzed. It was found that the simulated data resulting from the two lowest doses were described by monoexponential equations (equation 7 or 8), while data for the other doses were described by a biexponential equation (equation 9 or 10). Hence the low-dose data were fitted to equations 7 and 8, and the higher-dose data were fitted to equations 9 and 10 by nonlinear least-squares regression. Results of the computer fittings are shown in Table I . The monoexponential fittings were excellent, with almost all of the percent deviations being less than 1% and r z (1-E dev2/Z obs 2) and Corr (correlation coefficient for the linear regression of t7" on Y) being equal to 1.000. Similarly, the biexponential fittings were excellent, with all percent deviations being less than 1% except those at very low dose numbers, and r 2 and Corr being equal to 1.000. Table II 
~G+c~.
UValues of C~ ~.
Oral simulation: 
In therapeutic drug monitoring it may be more realistic to consider, say, 95% of the steady-state concentration. Figure 5 is a plot of the number of doses required to reach 95% of the minimum steady-state concentration Similar plots using data from the oral simulations did not exhibit as good linearity, but the trends were the same. Figure 6 shows results of fitting the computer-derived values of Cs~ ~" and C~s from the oral simulated data to equations 11 and 12, respectively. The estimated parameters are shown in Table III , where they are compared with estimates made using various linear transformations of equations 11 and 12. Computer fitting of the C~, D/z data gave an estimated value of VaVm of 0.731 g/day, which corresponds to a 1/~ value of 12.18, which is 1.5% higher than the known value used in the simulation. The estimated value of Km was 12.23, which is 1.9% higher than the known value of 12. These small errors could readily be accounted for as a result of using the trapezoidal rule to estimate the areas from just a few 
~6
points and the errors involved in the fitting~ Thus equation 12 does apply to oral data, and the true kinetic constants, V,, and Kin, are estimated. But in fitting of Cs~ , D/z data, shown in Fig. 6 , the estimated value the computer ' rain of VdV~ p was 0.709, corresponding to a V~ p value of 11.82, which is 1.5% lower than the known value of Vm, and the estimated value of K~ p was 9.45, which is 27% lower than the known value of Km of 12. Figure 7 Css , D/~" data from the intravenous simulation shows the results of fitting rain to equation 11. The estimated parameters are shown in Table II1 . The estimated value of ~1 l[Tapp vd~,, was 0.585, corresponding to an estimated value of V~, pp of 14.625, which is 2.5% lower than the known value of V,, of 15; the estimated value of Kam pp was 8.25, which is 31% lower than the Km value of 12. This explains why the "true" kinetic constants, Vm and Kin, appear in equation 12 derived from minimum steady-state concentrations, but are not the actual enzyme constants. This, therefore, applies to the same type of constants reported by Richens (5), Ludden et al. (6) , and Mullen (7). It is also of interest to see, in some cases, how much the constants estimated by other methods differ from those estimated by nonlinear least-squares fitting (Table III) .
DISCUSSION
The simulations have shown that when elimination kinetics is that of Michaelis and Menten the rate of accumulation is either mono-or biexponential, with the half-life corresponding to the smaller rate parameter being approximately linearly related to the final steady-state concentration. Thus, as the dose rate is increased, it requires proportionately more time to reach a given proportion of the final steady-state concentration. Since parallel Michaelis-Menten metabolite formation paths (19) and parallel Michaelis-Menten and first-order elimination pathways (20) aActual value used in the simulation was (60 x 12)/1000 = 0.720 g/day. bActual value used in the simulation was 12 mg/liter. CTheir equations 5 and 6 were used with all possible pairs of values; the reported value is the median. aActual value used in the simulation was (40 x 15)/1000 = 0.600 g/day.
information needed is one accurate serum level estimation in steady state, i.e. after at least 2 weeks on a constant intake of the drug. The time of day at which the sample is taken has not been allowed for because phenytoin is absorbed and metabolized relatively slowly. The usual fluctuation in serum levels seen throughout the day seldom exceeds 20%, particularly at therapeutic serum levels." Ludden et al. (6) Table III for estimated parameters.
in phenytoin dosage." The simulations show that the time that needs to be allowed depends on the dose rate of the drug.
If one wishes to estimate --mvapp and ~-,,~Tapp for a given patient, as done by Richens (5), Ludden et al.. (6) , and Mullen (7), then the simulations suggest a procedure as follows. Minimum steady-state concentrations, Inin C, , just before the next dose, should be measured on consecutive days, starting about 4-6 days after uniform therapy has been initiated or a change in dosage regimen has taken place. A difference plot should be prepared; if the difference data are linear (like the data in Fig. 2) , then an estimate of Cs mix for a given dose rate is readily made. If the dose rate is high and/or data are collected too early, the difference plot may be curved (like data in Fig. 3) , in which case one may either fit a parabola to make an estimate of Cs~ 'n or keep collecting data until the plot becomes linear, then extrapolate the linear portion. Thus the pharmacokinetic equations (e.g., equation 11) require estimates of Cs~ in for various D/'r values; use of just some C mln values, as apparently has been done to date, would lead to biased results. Assay error involved in measurement of the C, ~i" values does not C, , n values necessarily lead to errors in estimated parameters. A set of min was generated with equation 8 using Cs~ in = 100 and A1 =0.1, then 5% random error was added so that values were either 95% (-error) or 105% (+error) of the actual C rain values; for n = 1, 2, 3, 4, 7, 10, 15, 20, 25, and 30, the error was -, +, +, -, +, , , +, -, and +, respectively. Computer fitting of the C7 in data with the 5% random error to equation 11 gave estimates as follows: Csn~ in = 100.00 and A1 = 0.1000. Thus with inclusion of 5% random error in the data the theoretical constants were exactly estimated.
It was always highest for n = 1; then as n increased the ratio decreased and approached an asymptotic value at higher values of n. The asymptotic value of the ratio was lower the higher the dose. For the intravenous data the asymptotic ratios were 2.30, 1.87, 1.53, 1.29, and 1.15 for dose rates of 0.2, 0.3, 0.4, 0.5, and 0.6, respectively. For the oral data the asymptotic ratios were 1.58, 1.54, 1.38, 1.28, and 1.12 for dose ratios of 0.1, 0.15, 0.3, 0.4, and 0.6 g/day, respectively. Hence in the monitoring of phenytoin serum concentrations one would expect the degree of fluctuation in the concentrations throughout the day to be both dose and concentration dependent. These data support measurement of minimum concentrations just before the next dose.
